PeproStat Haemostat Study in Subjects Undergoing Liver Surgery
- Registration Number
- NCT02204930
- Lead Sponsor
- Haemostatix Ltd
- Brief Summary
The purpose of this First in Man study is to evaluate the safety and tolerability, as well as to explore efficacy of PeproStat, a new peptide based coagulant (haemostat), when used in patients undergoing open liver resection surgery.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
- Are able and willing to provide written informed consent to participate in this study, confirmed by signing the informed consent documents
- Adult males and females ≥18 years of age
- Female subjects must be post-menopausal. Post-menopausal status is defined as any of the following: natural menopause with menses >1 year ago; radiation induced oophorectomy with last menses >1 year ago; chemotherapy induced menopause with 1 year interval since last menses
- Willing and able to comply with all protocol requirements including follow-up
- Subject must have a haemoglobin ≥ 9.0 g/dL at screening
- Subject must have a platelet count ≥ 100,000/mm3 at screening
- Subject is undergoing a planned open liver resection
- Male subjects must be willing and able to use adequate contraception from enrollment through to the 30 day follow-up visit
- During the surgery, the subject presents an identified target bleeding site (TBS) with oozing, mild or moderate bleeding, which conventional surgical techniques are insufficient to control and would otherwise be a candidate for standard haemostats
- During the surgery, subject presents no intraoperative complications, other than bleeding, that may interfere with study assessments as judged by the investigator
Exclusion Criteria
- Subject is undergoing emergency surgical procedure
- Recipient of a liver transplant
- Females of child-bearing potential
- Active infection at the time of the liver resection
- International Normalized Ratio (INR) > 2.0 or APTT ratio > 2.0 at screening
- Fibrinogen level < 1.5g/L at screening
- History of thromboembolic disease and/or thrombophilia
- Any other disease or condition that may affect normal blood clotting, for example thrombocytopenia, as judged by the investigator
- A known history of anaphylaxis or allergic reaction to human albumin, PEGylated proteins, yeast or moulds, porcine products or other components in the IMP
- Participation in another investigational drug or device research study within 30 days before and after enrolment in the current study
- Current known or suspected alcohol and/or drug abuse or dependence at the time of screening
- Any concurrent medical, surgical, or psychiatric condition that may, in the investigator's opinion, affect the subject's willingness or ability to meet all study requirements during the study duration
- During the surgery, subject presents severe bleeding where use of a topical haemostat would be inappropriate
- Subject is taking any prohibited medications
- BMI at screening of ≥35
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Haemostat PeproStat PeproStat
- Primary Outcome Measures
Name Time Method Safety of PeproStat within 30 days after surgery and study treatment Incidence, severity, and relatedness of adverse events (AEs) and adverse drug reactions (ADRs).
- Secondary Outcome Measures
Name Time Method Assessment of efficacy of PeproStat in achieving haemostasis in open liver resection surgery During surgery Administered dose of PeproStat determined by number of sponges administered to a single bleeding site.
Trial Locations
- Locations (4)
Queen Elizabeth Hospital
🇬🇧Birmingham, United Kingdom
Addenbrooke's University Hospital
🇬🇧Cambridge, United Kingdom
Kings University Hospital
🇬🇧London, United Kingdom
Derriford Hospital
🇬🇧Plymouth, United Kingdom